{"title":"比替格拉韦/恩曲他滨/替诺福韦阿拉非米特治疗癌症和移植受者HIV/乙肝病毒合并感染","authors":"Jana K Dickter, Justine A Ross","doi":"10.17925/id.2023.2.1.31","DOIUrl":null,"url":null,"abstract":"For people with HIV/hepatitis B virus (HBV) co-infection who develop comorbidities that require polypharmacy, treatment may be complicated due to drug interactions and overlapping toxicities of medications received. As the population with HIV ages, there are more patients developing malignancies and undergoing transplantation, and management can be complicated. This review describes the best strategies for the treatment of a hypothetical patient with HIV/HBV co-infection who develops diffuse large B-cell lymphoma and ultimately undergoes autologous haematopoietic stem cell transplantation. In this theoretical case, the patient is treated with bictegravir/emtricitabine/tenofovir alafenamide. Situations arise where people with HIV have underlying antiretroviral drug resistance and HBV drug resistance that require optimization of their antiviral therapy. As these types of cases are seen commonly at our institution, we discuss special situations that develop during treatment, including immune reconstitution inflammatory syndrome, that require close monitoring and occasional treatment modifications during their course of therapy.","PeriodicalId":13671,"journal":{"name":"Infectious Diseases","volume":"201 1","pages":"0"},"PeriodicalIF":4.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bictegravir/Emtricitabine/Tenofovir Alafenomide for the Treatment of HIV/Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients\",\"authors\":\"Jana K Dickter, Justine A Ross\",\"doi\":\"10.17925/id.2023.2.1.31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For people with HIV/hepatitis B virus (HBV) co-infection who develop comorbidities that require polypharmacy, treatment may be complicated due to drug interactions and overlapping toxicities of medications received. As the population with HIV ages, there are more patients developing malignancies and undergoing transplantation, and management can be complicated. This review describes the best strategies for the treatment of a hypothetical patient with HIV/HBV co-infection who develops diffuse large B-cell lymphoma and ultimately undergoes autologous haematopoietic stem cell transplantation. In this theoretical case, the patient is treated with bictegravir/emtricitabine/tenofovir alafenamide. Situations arise where people with HIV have underlying antiretroviral drug resistance and HBV drug resistance that require optimization of their antiviral therapy. As these types of cases are seen commonly at our institution, we discuss special situations that develop during treatment, including immune reconstitution inflammatory syndrome, that require close monitoring and occasional treatment modifications during their course of therapy.\",\"PeriodicalId\":13671,\"journal\":{\"name\":\"Infectious Diseases\",\"volume\":\"201 1\",\"pages\":\"0\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/id.2023.2.1.31\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/id.2023.2.1.31","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Bictegravir/Emtricitabine/Tenofovir Alafenomide for the Treatment of HIV/Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients
For people with HIV/hepatitis B virus (HBV) co-infection who develop comorbidities that require polypharmacy, treatment may be complicated due to drug interactions and overlapping toxicities of medications received. As the population with HIV ages, there are more patients developing malignancies and undergoing transplantation, and management can be complicated. This review describes the best strategies for the treatment of a hypothetical patient with HIV/HBV co-infection who develops diffuse large B-cell lymphoma and ultimately undergoes autologous haematopoietic stem cell transplantation. In this theoretical case, the patient is treated with bictegravir/emtricitabine/tenofovir alafenamide. Situations arise where people with HIV have underlying antiretroviral drug resistance and HBV drug resistance that require optimization of their antiviral therapy. As these types of cases are seen commonly at our institution, we discuss special situations that develop during treatment, including immune reconstitution inflammatory syndrome, that require close monitoring and occasional treatment modifications during their course of therapy.
期刊介绍:
Infectious Diseases (formerly Scandinavian Journal of Infectious Diseases) is a peer-reviewed journal publishing articles on all aspects of human infection, including pathogenesis, diagnosis, and treatment of infectious diseases, and also on medical microbiology and epidemiology